A multicentred phase III comparative clinical trial of mesigyna, cyclofem and injectable no. 1 given monthly by intramuscular injection to Chinese women

Sang, Guo-wei; Shao, Qing-xiang; Ge, Ruoff; Ge, Jingwen; Chen, J.K.; Song, Shuai; Fang, Kewei; He, Mian; Luo, Shaowei; Chen, S.F.; Chen, X.B.; Li, M.X.; Wu, Shangchun; Sun, G.L.; Zhou, Haibin; Zhang, S.F.; Zhu, Linda; Ye, B.L.; Zhang, J.H.; Ma, Fang; Jiang, Binghu; Zhou, Zhongyu; Dong, Qianqian; Shen, Hua; Liu, Y.X.; Shao, Jianing; Wang, S.X.; Ming, He; Zhu, Zhaohui; Cheng, Helen; Chen, S.H.; Yu, Juan; Zhang, Z.Y.; Qing, Yao; Wang, X.Y.; Hall, Peter; d’Arcangues, Catherine; Snow, Rachel

doi:10.1016/0010-7824(95)00013-z

Cited by 27 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several dose-ranging studies were conducted during the 1970s to evaluate the efficacy and safety of MPA/E 2 C in various dosing combinations (Newton, 1994;Sang et al, 1995;World Health Organization [WHO], 1988). Of the doses studied, the combination of MPA 25 mg and E 2 C 5 mg provided the best efficacy (i.e., complete suppression of ovulation and no pregnancies) and the most regular bleeding patterns.…”

Section: Pharmacokinetics Of Mpa/e 2 Cmentioning

confidence: 99%

See 1 more Smart Citation

Contraceptive Efficacy and Patient Acceptance of Lunelle

Freeman

2002

Journal of the American Academy of Nurse Practitioners

View full text Add to dashboard Cite

Oral contraceptives are the most popular hormonal birth control method in the United States; however, typical use is associated with higher failure rates than those observed with perfect use because of poor compliance. Poor compliance has been attributed in part to the need for daily administration. A new contraceptive method that does not require daily administration and is readily reversible may be suitable for many women, resulting in better overall efficacy.

show abstract

Section: Pharmacokinetics Of Mpa/e 2 Cmentioning

confidence: 99%

“…The early data regarding the pharmacokinetics of MPA/E 2 C are limited by the small size and number of studies that were conducted (Newton, 1994;Sang et al, 1995;WHO, 1988). In addition, these studies employed hormonal assay techniques that are now considered outdated.…”

Section: Pharmacokinetics Of Mpa/e 2 Cmentioning

confidence: 99%

Contraceptive Efficacy and Patient Acceptance of Lunelle

Freeman

2002

Journal of the American Academy of Nurse Practitioners

View full text Add to dashboard Cite

show abstract

“…Thus the optimal compositions were found to be 25 mg DMPA plus 5 mg oestradiol cypionate for Cyclofem, and 50 mg NET-EN plus 5 mg oestradiol valerate for Mesigyna. Subsequent pharmacokinetic, pharmacodynamic [57,58] and metabolic studies [59,60,61] and clinical trials [62,63,64,65,66,67] established the efficacy and safety of both preparations. Introductory studies followed in a number of countries [68,69], illustrating a variety of experiences and service delivery issues.…”

Section: The Work Of the Programmementioning

confidence: 99%

The Special Programme of Research in Human Reproduction: Forty Years of Activities to Achieve Reproductive Health for All

Benagiano¹,

d’Arcangues²,

Requejo³

et al. 2012

Gynecol Obstet Invest

View full text Add to dashboard Cite

The Special Programme of Research in Human Reproduction (HRP), co-sponsored by the UNDP, UNFPA, WHO, and the World Bank, is celebrating 40 years of activities with an expansion of its mandate and new co-sponsors. When it began, in 1972, the main focus was on evaluating the acceptability, effectiveness, and safety of existing fertility-regulating methods, as well as developing new, improved modalities for family planning. In 1994, HRP not only made major contributions to the Plan of Action of the International Conference on Population and Development (ICPD); it also broadened its scope of work to include other aspects of health dealing with sexuality and reproduction, adding a specific perspective on gender issues and human rights. In 2002, HRP’s mandate was once again broadened to include sexually transmitted infections and HIV/AIDS and in 2003 it was further expanded to research activities on preventing violence against women and its many dire health consequences. Today, the work of the Programme includes research on: the sexual and reproductive health of adolescents, women, and men; maternal and perinatal health; reproductive tract and sexually transmitted infections (including HIV/AIDS); family planning; infertility; unsafe abortion; sexual health; screening for cancer of the cervix in developing countries, and gender and reproductive rights. Additional activities by the Programme have included: fostering international cooperation in the field of human reproduction; the elaboration of WHO’s first Global Reproductive Health Strategy; work leading to the inclusion of ICPD’s goal ‘reproductive health for all by 2015’ into the Millennium Development Goal framework; the promotion of critical interagency statements on the public health, legal, and human rights implications of female genital mutilation and gender-biased sex selection. Finally, HRP has been involved in the creation of guidelines and tools, such as the ‘Medical eligibility criteria for contraceptive use’, the ‘Global handbook for family planning providers’, the ‘Definition of core competencies in primary health care’, and designing tools for operationalizing a human rights approach to sexual and reproductive health programmes.

show abstract

“…The first product is medroxyprogesterone acetate 25 mg with estradiol cypionate 5 mg and the second is norethisterone enanthate 50 mg with estradiol valerate. Compared with progestogenonly injectables, combined injectables disturb bleeding patterns less 37 and allow earlier return to ovulation after discontinuation. 38 Bleeding patterns are similar to the combined pill, patch or ring.…”

Section: Injectable Contraceptionmentioning

confidence: 99%

New technologies in contraception

Rowlands

2008

BJOG

View full text Add to dashboard Cite

New technologies in both reversible contraception and sterilisation are described. The review includes recent advances in the development of oral contraception, emergency contraception, injectable contraception, vaginal rings, subdermal implants, transdermal contraception, intrauterine devices, spermicides and barrier methods. It also covers methods of transcervical female sterilisation and more easily reversible male sterilisation.The emphasis is on the technology and its safety and effectiveness. Hormonal delivery systems are described in some detail. Mention is also made of research into vaccines and male hormonal methods, where progress has been disappointing.

show abstract

A multicentred phase III comparative clinical trial of mesigyna, cyclofem and injectable no. 1 given monthly by intramuscular injection to Chinese women

Cited by 27 publications

References 7 publications

Contraceptive Efficacy and Patient Acceptance of Lunelle

Contraceptive Efficacy and Patient Acceptance of Lunelle

The Special Programme of Research in Human Reproduction: Forty Years of Activities to Achieve Reproductive Health for All

New technologies in contraception

Contact Info

Product

Resources

About